Harrow is a small biotech company focused on acquiring and commercializing ophthalmic pharmaceutical products in the US.
Investor's Business Daily on MSN
Harrow Earns Relative Strength Rating Upgrade
Over 100 years of market history shows that the best-performing stocks typically have an 80 or better RS Rating in the early ...
Harrow recently experienced a 24% share price increase over the last quarter, coinciding with its announcement of a $250 million debt financing via senior unsecured notes. This announcement comes at a ...
Harrow (NASDAQ:HROW) has priced an underwritten public offering of 3.38 million shares of its common stock at a price of $17.75/share for expected gross proceeds of $60 million. The stock is down 1.37 ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the fourth quarter and ...
Announces Commitment for New $40 Million Revolving Credit Facility Issues Conditional Notice of Redemption of 11.875% Senior Notes due 2027 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback